



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

MAR 6 2007 1033 7 MAR 12 A9:39

Robert W. Pollock
Senior Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

Re: Docket No. 2006P-0372/CP1

Dear Mr. Pollock:

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition dated September 7, 2006. Your petition requests that the Agency determine whether Mepron (atovaquone) tablets, 250 milligrams (mg), the subject of new drug application (NDA) 20-259, were voluntarily withdrawn from sale for safety or effectiveness reasons.

FDA has been unable to reach a decision on your petition due to the need to address other Agency priorities. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as possible given the numerous demands on the Agency's resources.

Sincerely,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

2006P-0372

LET 1